• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

L-dopa pharmacokinetics in plasma and cisternal and lumbar cerebrospinal fluid of monkeys.

作者信息

Hammerstad J P, Woodward W R, Gliessman P, Boucher B, Nutt J G

机构信息

Department of Neurology, Oregon Health Sciences University, Portland 97201.

出版信息

Ann Neurol. 1990 May;27(5):495-9. doi: 10.1002/ana.410270507.

DOI:10.1002/ana.410270507
PMID:2360790
Abstract

The pharmacokinetics of levodopa (L-dopa) in plasma and in cisternal and lumbar cerebrospinal fluid (CSF) were studied in Rhesus monkeys that were given 2- to 3-hour intravenous infusions of L-dopa. Steady-state L-dopa concentrations in cisternal CSF correlated well with plasma levels, and yielded a CSF:plasma ratio of 0.17. The disappearance of L-dopa from plasma and cisternal CSF compartments fits an open, two-compartment pharmacokinetic model. Although slower, the distribution and elimination half-lives for L-dopa from cisternal CSF (8.9 and 49.2 minutes, respectively) were of a similar magnitude to those from plasma (4.9 and 33.2 minutes, respectively). If cisternal CSF reflects brain extracellular fluid, then plasma pharmacokinetics of L-dopa are a reasonable approximation of those in the brain. In contrast to cisternal CSF, the disappearance of L-dopa from lumbar CSF fits an open, one-compartment model with an elimination half-life of 100 minutes. This indicates that the lumbar CSF compartment is unsuitable for investigation of the pharmacokinetics of L-dopa in the brain.

摘要

相似文献

1
L-dopa pharmacokinetics in plasma and cisternal and lumbar cerebrospinal fluid of monkeys.
Ann Neurol. 1990 May;27(5):495-9. doi: 10.1002/ana.410270507.
2
Cerebrospinal fluid pharmacokinetics of intrathecal morphine sulfate and D-Ala2-D-Leu5-enkephalin.鞘内注射硫酸吗啡和D-丙氨酸2-D-亮氨酸5-脑啡肽的脑脊液药代动力学
Ann Neurol. 1986 Aug;20(2):218-22. doi: 10.1002/ana.410200207.
3
Plasma and cerebrospinal fluid pharmacokinetics of acivicin in Ommaya reservoir-bearing rhesus monkeys.阿西维辛在携带奥马亚贮液器的恒河猴中的血浆和脑脊液药代动力学。
Cancer Treat Rep. 1982 Jun;66(6):1333-41.
4
Plasma and cerebrospinal fluid pharmacokinetics of SU5416 after intravenous administration in nonhuman primates.非人类灵长类动物静脉注射SU5416后的血浆和脑脊液药代动力学。
Cancer Chemother Pharmacol. 2004 Jan;53(1):39-42. doi: 10.1007/s00280-003-0683-z. Epub 2003 Oct 9.
5
Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates.非人类灵长类动物中静脉注射奥沙利铂、顺铂和卡铂的血浆及脑脊液药代动力学
Clin Cancer Res. 2005 Feb 15;11(4):1669-74. doi: 10.1158/1078-0432.CCR-04-1807.
6
Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates.培美曲塞在非人灵长类动物静脉给药后的血浆和脑脊液药代动力学。
Cancer Chemother Pharmacol. 2007 Mar;59(4):461-6. doi: 10.1007/s00280-006-0285-7. Epub 2006 Jul 20.
7
Cerebrospinal fluid pharmacokinetics of intraventricular and intravenous aziridinylbenzoquinone.脑室注射和静脉注射氮丙啶基苯醌的脑脊液药代动力学
Cancer Res. 1984 Apr;44(4):1698-701.
8
Uptake kinetics of 2',3'-dideoxyinosine into brain and cerebrospinal fluid of rats: intravenous infusion studies.2',3'-双脱氧肌苷在大鼠脑和脑脊液中的摄取动力学:静脉输注研究
J Pharmacol Exp Ther. 1990 Apr;253(1):113-8.
9
L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans.恒河猴和人类脑脊液中L-天冬酰胺酶的药代动力学及天冬酰胺水平
Cancer Res. 1981 Nov;41(11 Pt 1):4554-8.
10
Plasma and cerebrospinal fluid pharmacokinetics of rebeccamycin (NSC 655649) in nonhuman primates.非人类灵长类动物中瑞贝卡霉素(NSC 655649)的血浆和脑脊液药代动力学
Cancer Chemother Pharmacol. 2004 Aug;54(2):127-30. doi: 10.1007/s00280-004-0787-0. Epub 2004 May 18.

引用本文的文献

1
Drug transport into the central nervous system: using newer findings about the blood-brain barriers.药物向中枢神经系统的转运:利用关于血脑屏障的新发现。
Drug Deliv Transl Res. 2012 Jun;2(3):152-9. doi: 10.1007/s13346-012-0058-2.
2
Focal striatal dopamine may potentiate dyskinesias in parkinsonian monkeys.局部纹状体多巴胺可能会增强帕金森病猴的运动障碍。
Exp Neurol. 2006 Feb;197(2):363-72. doi: 10.1016/j.expneurol.2005.10.022. Epub 2005 Dec 9.
3
Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.
用于治疗帕金森病的药物的临床药代动力学和药效学特性。
Clin Pharmacokinet. 2002;41(4):261-309. doi: 10.2165/00003088-200241040-00003.